Cell-Mediated Therapies for Infectious Disease Summit

Memo

In the fight against emerging coronavirus variants, the need for long-lasting immunity is greater than ever… which is why the field is looking beyond antibodies and turning to T cells. The Cell-Mediated Therapies for Infectious Disease Summit is the first industry-dedicated meeting to understand and stimulate the immune cell response to develop long term immune memory to infectious disease pathogens. Join over 80 industry and academic leaders pioneering this new paradigm of research, and for the first time discuss novel advances in t-cell epitope-directed vaccines, as well as CAR-T, TCR and NK cell therapies designed to provoke durable immunity. With strategic insight and clinical advances shared from Gilead, Merck, Vaccibody, TScan Therapeutics and more, join the discussion to assess: - Bioinformatic tools to identify immunogenic targets Vaccine design and delivery to trigger strong T cell responses- Bridge the gap from translatable preclinical models to IND approval- Leave this meeting with a greater understanding of next-generation approaches to target, prevent and cure HIV, EBV and SARS-CoV-2 infection. Tickets https://go.evvnt.com/753957-2?pid=5569Brochure https://go.evvnt.com/753957-3?pid=5569 Prices:Conference + 2 Workshops - Drug Developer USD 2697.00Conference + 1 Workshop - Drug Developer USD 2348.00Conference Only - Drug Developer USD 1999.00Conference + 2 Workshops - Academic Pricing USD 2197.00Conference + 1 Workshop - Academic Pricing USD 1898.00Conference Only - Academic Pricing USD 1599.00Conference + 2 Workshops - Standard Pricing USD 3297.00Conference + 1 Workshop- Standard Pricing USD 2898.00Conference Only - Standard Pricing USD 2499.00 Speakers: Marc Van Dijk, Chief Technology Officer, AgenTus, Mark Exley, Vice President, Cellular Immunology, AgenTus, Xiaokui Zhang, Chief Scientific Officer, Celularity, Catherine Bollard, Director, Center for Cancer & Immunology, Children’s National Medical Center, Marcela Henao Tamayo, Assistant Professor, Microbiology, Immunology & Pathology, Colorado State University, Raymond Goodrich, Executive Director, Infectious Disease Research Center, Colorado State University, Lenny Moise, Director, Vaccine Research, EpiVax, Inc., Wade Blair, Executive Director, Biology, Gilead Sciences, Roman Yelensky, Executive Vice President & Chief Technology Officer, Gritstone Oncology, Renata Stripecke, Professor & Head of Laboratory, Hannover Medical School, Lucy Dorrell, Head of Disease Biology, Infectious Diseases, Immunocore, Corey Casper, Chief Executive Officer, Infectious Disease Research Institute, Bonnie Howell, Executive Director, Infectious Disease & Vaccines, Merck, Devon Shedlock, Senior Vice President, R&D Poseida, Therapeutics, Rajiv Khanna, Professor, Senior Scientist & Deputy Coordinator of Immunology Department, QIMR Berghofer, Paul Thomas, Professor, St Jude Children’s Research Hospital, Gavin MacBeath, Chief Scientific Officer, TScan Therapeutics, Scott Kitchen, Associate Professor of Medicine, Director, UCLA Humanized Mouse Core Laboratory, UCLA, Drew Weissman, Professor of Medicine, University of Pennsylvania, Agnete Fredriksen, President & Chief Scientific Officer, Vaccibody   Time: On Tuesday July 20, 2021 at 9:30 am (ends Thursday July 22, 2021 at 4:00 pm)